Acumen Pharmaceuticals reported its first quarter 2025 financial results, with cash, cash equivalents, and marketable securities totaling $197.9 million as of March 31, 2025. This capital is expected to fund operating expenses and capital expenditure requirements into early 2027. The company reported a net loss of $28.8 million for the quarter, compared to $14.87 million in the prior year.
Operating expenses for Q1 2025 were $30.4 million, an increase from $17.8 million in Q1 2024, primarily driven by a $12.9 million rise in Research and Development expenses. This increase was largely due to higher CRO costs for the ALTITUDE-AD trial and manufacturing and materials.
The company reiterated its expectation to report topline results for the Phase 2 ALTITUDE-AD study of sabirnetug in late 2026. The financial runway into early 2027 is projected to extend beyond this anticipated data readout, providing stability through a key value inflection point.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.